Beijing-Based Biopharma Firms Report Breakthroughs in Innovative Drug Development

Our Staff Reporter (ZHAO Yuhan) Innovative target drugs, innovative ophthalmic gene drugs, personalized tumor neoantigen vaccines... Recently, there have been frequent reports of successful research and development from innovative pharmaceutical companies within the Future Science City's Life Valley. Among them,InnoCareThe independently developed anti-tumor innovative drug has completed the first patient dosing.

InnoCare, an innovative pharmaceutical company, recently announced that the first patient has been dosed with its self-developed novel ADC (Antibody-Drug Conjugate) ICP-B794. This innovative drug targets the novel B7-H3, for which there are currently no approved therapies globally, making the new drug potentially capable of filling this gap and offering patients a new treatment option. This innovation stems from the company’s self-developed ADC platform, with a differentiated design enabling precise targeting of tumor cells while reducing off-target effects, bringing hope to patients with various solid tumors such as lung cancer, esophageal cancer, nasopharyngeal cancer, and prostate cancer.

Jianda Jiuzhou's self-developed ophthalmic gene therapy drug, GA001 Injection, has also achieved new progress recently. The drug has been granted Fast Track designation by the U.S. Food and Drug Administration, which will greatly accelerate the clinical trial and marketing registration process. In China, the Investigational New Drug (IND) application for GA001 Injection was accepted by the Center for Drug Evaluation of the National Medical Products Administration in August this year. The drug has shown remarkable results in treating advanced blindness caused by retinitis pigmentosa.

In addition, NeoCura's self-developed mRNA personalized tumor neoantigen vaccine XH001 has recently initiated a Phase I clinical study at Peking Union Medical College Hospital. This is the first mRNA personalized tumor neoantigen vaccine in China to enter the clinical stage, and globally, no similar products have been approved for marketing.